Rituximab
Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Explore 7 assets in Gastric Mucosa-Associated Lymphoid Tissue Lymphoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07583810CT.gov Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rituximab (this asset) | City of Hope Medical Center | P2 | CCC · 53 |
| Bismuth Subcitrate | National Taiwan University Hospital | P2 | CCC |
| Nemtabrutinib | City of Hope Medical Center | P2 | CCC |
| Esomeprazole | National Taiwan University Hospital | P2 | CCC |
| Tetracycline | National Taiwan University Hospital | P2 | CCC |
| Orelabrutinib | Fudan University | P2 | CCC |
| Vandazole | National Taiwan University Hospital | P2 | CCC |
| 1H-BENZIMIDAZOLE, 2-(((4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL)METHYL)SULFINYL)-, SODIUM SALT, HYDRATE (1:1:1) | Eisai Co., Ltd. | Unk | D |
| Clarithromycin | National Health Research Institutes, Taiwan | N/A | D |
+2 more in the Gastric Mucosa-Associated Lymphoid Tissue Lymphoma cohort
Other indications for Rituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoblastic Lymphoma | — | P4 | BBB · 75 |
| Grade III Lymphomatoid Granulomatosis | — | P2 | BBB · 74 |
| Testicular Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rituximab in Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g-1-human-mouse-monoclonal-idec-c2b8-gamma1-chain-anti-human-antigen-cd-20-disulfide-with-human-mouse-monoclonal-idec-c2b8-kappa-chain-dimer-gastric-mucosa-associated-lymphoid-tissue-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →